ecancermedicalscience

Case Report

Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour

1 Apr 2021
Abhenil Mittal, Aarushi Gupta, Sameer Rastogi, Adarsh Barwad, Swati Sharma

Background: Infantile inflammatory myofibroblastic tumour (IMT) is rare and the majority are driven by anaplastic lymphoma kinase (ALK) rearrangements. Previous literature on the use of ALK inhibitors in paediatric IMTs is extremely limited with no published literature on the use in infants. Crizotinib and ceritinib are two ALK inhibitors which are available and have been used in IMTs; however, ceritinib is much more affordable in the low- and middle-income country (LMIC) setting than crizotinib.

Case: An 11-month-old child, who had undergone surgery for mesenteric IMT at the age of 3 months, had an unresectable recurrence with soft tissue deposits in the subdiaphragmatic location abutting the spleen and paravesical location. As surgery would have entailed splenectomy and partial cystectomy, she was treated with low-dose ceritinib (300 mg/m2/day) with which she had a near-complete response without any toxicity.

Discussion and conclusion: This is the first report of the use of ceritinib at a lower dose for infantile IMT having immense practical applications for the low- and middle-income setting.

Related Articles

Nontuthuzelo IM Somdyala, Linda Mbuthini, Borna Müller, Nomfuneko Sithole, Akhona Ncinitwa, Debbie Bradshaw
Arjun Gurmeet Singh, Devendra Chaukar, Sudeep Gupta, CS Pramesh, Richard Sullivan, Pankaj Chaturvedi, Rajendra Badwe
Severyn Ferneza, Markiyan Fetsych, Roman Shuliak, Halyna Makukh, Natalia Volodko, Roman Yarema, Tara Fetsych
Eduardo Payet, Joan Perez, Gustavo Sarria, Silvia Neciosup, Francisco Berrospi, Sheila Vilchez, Jorge Dunstan, Ronald Perez, Mauricio Vassallo, Santiago Salgado, Nanto Caparachín, Joseph A Pinto, Alexis Holguin